Skip to Content

Webcast Alert: Isis Pharmaceuticals Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium

CARLSBAD, Calif., October 01, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast:

    What:      New ISIS 301012 Phase 2 Clinical Data Presented at DALM

    When:      Monday, October 8, 2007, at 8:00 a.m. ET / 5:00 a.m. PT


    How:       Live on the Internet.  Simply log onto our web site listed


    Contacts:  Kristina Lemonidis

               Associate Director, Investor Relations

               (760) 603-2490

               Amy Blackley, Ph.D.

               Manager, Corporate Communications

               (760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at

CONTACT: Kristina Lemonidis Associate Director, Investor Relations,+1-760-603-2490, or Amy Blackley, Ph.D., Manager, Corporate Communications,+1-760-603-2772, both of Isis Pharmaceuticals, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:ISIS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: October 2007